Augmedix AUGM 深 沪
等待开盘 10-01 09:30:00 美东时间
33.63
+0.021
+0.06%
华盛通- 最 高33.63
- 今 开33.62
- 成交量 1.66万股
- 最 低 33.60
- 昨 收 33.6092
- 总市值 1849.65万
- 52周最高 33.63
- 市盈率 静 --
- 换手率 3.01%
- 52周最低 30.83
- 委 比 0.00%
- 总股本 55.00万
- 历史最高 33.63
- 量 比 10.75
- 振 幅 0.09%
- 历史最低 30.83
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Augmentum Fintech Celebrates Gemini’s Successful IPO
The latest announcement is out from Augmentum Fintech PLC ( ($GB:AUGM) ). Augme...
09-15 14:23
Creative Medical Technologies will be issued US patent number 12,391,925 tomorrow titled "PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES BY AUGMENTATION OF MYELOID SUPPRESSOR CELL ACTIVITY"
https://x.com/patentgrants/status/1957532080155562158?s=46&t=dtUiyC3dUs5yGRgT9qYHWg
08-19 04:02
Augmentum Fintech PLC Releases June 2025 Factsheet
Augmentum Fintech PLC ( ($GB:AUGM) ) just unveiled an announcement. Augmentum F...
08-14 14:26
Augmentum Fintech Approves New Investment Adviser Appointment
An update from Augmentum Fintech PLC ( ($GB:AUGM) ) is now available. Augmentum...
07-24 17:52
Augmentum Fintech PLC Proposes Investment Advisory Structure Amendment
Augmentum Fintech PLC ( ($GB:AUGM) ) has shared an update. Augmentum Fintech PL...
07-01 14:28
Syndax Pharmaceuticals Announces That The FDA Has Granted Priority Review For Its Supplemental New Drug Application For Revuforj In Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
PDUFA action date set for October 25, 2025 –– sNDA being reviewed under FDA's RTOR program –– Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar
06-25 04:03
Augmentum Fintech PLC Announces Annual Results and Investor Events
Augmentum Fintech PLC ( ($GB:AUGM) ) just unveiled an update. Augmentum Fintech...
06-16 14:19
Syndax Presents New Revuforj (revumenib) Data In Relapsed/Refractory mNPM1 And NUP98r Acute Leukemia From AUGMENT-101 Trial At EHA 2025
26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population.– Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior
06-12 19:03
Augmentum Fintech Announces Capital Markets Day
Augmentum Fintech PLC ( ($GB:AUGM) ) just unveiled an update. Augmentum Fintech...
05-21 14:22
Syndax Pharma Publishes Data From Pivotal Phase 2 Portion Of AUGMENT-101 Trial Of Revumenib In Patients With R/R mNPM1 Acute Myeloid Leukemia In Blood
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial –– Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate –– sNDA
05-08 04:03
